Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.
about
Restrictive and diversifying elements of the anti-myelin/oligodendrocyte glycoprotein antibody response in primate experimental allergic encephalomyelitis.Inflammation in white matter: clinical and pathophysiological aspects.Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid.Peptide reactivity between multiple sclerosis (MS) CSF IgG and recombinant antibodies generated from clonally expanded plasma cells in MS CSF.An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis.Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiologyThe role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis.Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis.Immunoadsorption patients with multiple sclerosis: an open-label pilot study.Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort.MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosisIdentification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.Environmental pathways to autoimmune diseases: the cases of primary biliary cirrhosis and multiple sclerosis.Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein.B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseasesFunctional identification of pathogenic autoantibody responses in patients with multiple sclerosis.Autoantigen conformation influences both B- and T-cell responses and encephalitogenicityAntimyelin antibodies and the risk of relapse in patients with a primary demyelinating event.Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.Contribution of peptides to multiple sclerosis research.Toward biomarkers in multiple sclerosis: new advances.B-cells and humoral immunity in multiple sclerosis. Implications for therapy.Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis.Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosisEarly treatment of multiple sclerosis: a Latin American experts meeting.B cells contribute to MS pathogenesis through antibody-dependent and antibody-independent mechanisms.What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease.Anti-myelin antibodies in multiple sclerosis: clinically useful?Relevant antibody subsets against MOG recognize conformational epitopes exclusively exposed in solid-phase ELISA.Serum IgG repertoire in clinically isolated syndrome predicts multiple sclerosis.Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF.Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations
P2860
Q30810623-5026D728-0339-42A4-8025-C1346DE76E93Q31047396-9874D32F-181C-481B-823C-2F5E4AE3616FQ33745475-10AAD5B4-F475-4DF9-B2E6-E7EA1CCB1020Q33777821-F16017DF-3019-4BF2-B94B-07DDE5AA5E48Q33900554-AFB9F643-1360-4316-AC7A-64D308198AC1Q34048094-45499C4B-9B75-46C2-83C3-6E5E6AC4F4A5Q34468304-F619AAAD-E83C-45C1-95D9-7B0A649BB396Q34479121-6930CA68-9934-4ACE-B3E1-813DEFBA00BDQ34636372-6E6A8077-1485-4558-82DE-A8D13E585EEFQ34650883-95955EB6-ADB9-4A39-B301-BBF1511BA3ECQ34654987-FFA2C0B4-DD17-4FBD-AB51-D1FB63C35759Q35208073-A953CA7E-032F-4F2D-BB08-30F4D338B989Q35231795-6A03096A-D339-4AC9-BFE5-46F70DE9D5F5Q35539775-46FF32BA-B921-4648-97FD-6A5DDB5B5728Q35674181-6968157E-9A04-4843-83FF-9E8C245511C6Q35891689-EEE35AB3-0DC3-40D4-8DF7-9D7D803F6E49Q35903957-EFA3686F-D047-4DB0-A0E5-B0C592FB64A7Q35986699-7EDFF2E0-E502-4819-B915-547ABBF9895CQ36007039-1BB8A151-B8E9-46DA-AD47-408EB324AD01Q36142086-A79253E1-F56B-47BF-8EF5-115B198BB0B0Q36194449-85EB8105-9643-4542-B4D1-9593A33C1EFDQ36414628-27D84975-024D-4655-9967-CA8A8DE16BF3Q36492380-887C76D7-A9A0-4078-878B-56093F5C512CQ36981274-E3878379-F95F-41B5-972C-995143F38E09Q37324279-F97CBFFC-445F-483D-A8D2-6CA25D635271Q37400955-D8E906F2-C2B8-4418-AEAA-EC828E7AA00DQ37481523-C020A886-1492-4E6C-8760-BCE399BB0E6FQ37645629-7F65FC6F-FA4F-4CD2-B88B-1F57DF0A6B9AQ38018052-7230842D-1E07-4F20-8251-0378B91B92A6Q38088747-3322EDA1-657B-4F01-A5D6-226203B53454Q42718406-21D6B52D-4EF8-407F-93F7-9570EC9C420BQ46390509-DA5E1A3B-E801-4710-B3D5-A5A80AD63B3FQ48696793-D127F47D-6078-4482-991A-ED84867593ADQ51763866-EC0B160D-3645-4DE5-8C4F-72CE5F22C4B8Q59273833-01D5447C-40A5-4E55-9F95-5F2582BF8FC6
P2860
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.
@en
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.
@nl
type
label
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.
@en
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.
@nl
prefLabel
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.
@en
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.
@nl
P2093
P1433
P1476
Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects.
@en
P2093
Bonifacio E
Franciotta D
Zanaboni S
P304
P356
10.1212/01.WNL.0000127615.15768.AE
P407
P577
2004-06-01T00:00:00Z